Immunocore
Chemicals & Related Products · United Kingdom · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
92 Park Drive, Abingdon, Oxfordshire, OX...Phone Number
+441235438600Website
www.immunocore.comRevenue
$412.8 MillionStock Symbol
IMCRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Immunocore
Founded in 2008, Immunocore Limited is a privately owned British clinical-stage biotechnology company. It develops biological drugs to treat cancer, infectious diseases, and autoimmune diseases using soluble T-cell receptor technology. They are headquartered in Milton, United Kingdom.Explore more
Immunocore Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunocore your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Immunocore launches new products
Click to see if Immunocore had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Immunocore has new funding data
Congratulate Masked Content for being promoted to Masked Content at Immunocore
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Immunocore recently announced quarterly report
Check out if Immunocore is spiking on competitors!
Immunocore, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Immunocore has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Immunocore
Compare insights from companies similar to Immunocore, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$65.1M
501-1,000
Public
$485.9M
2008
MS
Mark StielowVice President, Manufacturing & Technical Operations (US)
Company Profile Activity
Activity Insights
Immunocore is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immunocore is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immunocore.
Immunocore financials insights
Gather financial insights about Immunocore, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$320M
2020
Series B
$130M
2021
Series C
$75M
Stock Offering
$297.1M
Immunocore Tech Stack
A closer look at the technologies used by Immunocore
See more technologies
Most Recent Scoops
Open Position
Person-Based
New Hire, Partnership
Open Position
Open Position
Open Position
Immunocore News & Media
Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term?
Immunocore Holdings plc (NASDAQ:IMCR) is one of the best small cap stocks to buy for the long term. Immunocore Holdings plc (NASDAQ:IMCR) announced on May 31 updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma, with the data presented in a poster at the 2026 American Society of Clinical […]Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanomaImmunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business updateKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Read more news
Top Chemicals & Related Products Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunocore
Sign Up For FreeTo access detailed company insights
Founded in 2008, Immunocore Limited is a privately owned British clinical-stage biotechnology company. It develops biological drugs to treat cancer, infectious diseases, and autoimmune diseases using soluble T-cell receptor technology. They are headquartered in Milton, United Kingdom.... Read More
